Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
VCYT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.61 - $47.32
Previous CloseN/A
Volume253.49K
Average Volume (3M)1.87M
Market Cap
$2.36B
Enterprise Value$1.85B
Total Cash (Recent Filing)$320.72M
Total Debt (Recent Filing)$50.65M
Price to Earnings (P/E)90.3
Beta1.60
Next Earnings
Nov 11, 2025EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding78,671,585
10 Day Avg. Volume1,784,556
30 Day Avg. Volume1,865,779
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue3.86
Enterprise Value/Gross Profit5.73
Enterprise Value/Ebitda31.47
Forecast
1Y Price Target
$39.00Price Target Upside29.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Financial PerformanceVeracyte's second-quarter results were positive across all key core metrics and updates.
Revenue GrowthDecipher momentum continues with 24% year-over-year revenue growth, while Afirma also saw solid performance in the quarter.
Bears Say
Market CompetitionThe rapidly evolving competitive and IP dynamics in the MRD market bear watching.
Reimbursement ChallengesNasal Swab reimbursement is unlikely to fall in place until 2028 or later, considering the NIGHTINGALE enrollment expected to complete in 3Q25.
Veracyte News
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $22.61 and its highest was $47.32 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is $2.36B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Nov 11, 2025 which is in 87 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Aug 06, 2025. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.264 by $0.176.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.32.
How many shares outstanding does Veracyte have?
Veracyte has 78,671,585 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of $0.44 in its last earnings report, beating expectations of $0.264. Following the earnings report the stock price went up 15.478%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in VCYT
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.00 (29.83% Upside)
$39.00 (29.83% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 232.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 19.5%
Last 30 Days ▲ 19.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.68%
12-Months-Change
Fundamentals
Return on Equity
2.24%
Trailing 12-Months
Asset Growth
8.89%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. is a genomic diagnostics company that focuses on improving patient outcomes through the development and commercialization of diagnostic tests for patients with cancer and other diseases. The company operates primarily in the healthcare sector, offering innovative solutions that enhance the accuracy of diagnoses and help physicians make informed treatment decisions. Veracyte's core products include its proprietary genomic tests, such as the Afirma Genomic Sequencing Classifier for thyroid cancer and the Percepta Genomic Sequencing Classifier for lung cancer, which are designed to reduce unnecessary surgeries and improve patient management.
VCYT Company Deck
VCYT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Veracyte's earnings call was positive overall, with strong revenue and volume growth, significant strategic milestones, and promising future product launches. While there were some financial challenges such as a decline in product revenue and increased operating expenses, the positive highlights significantly outweighed the lowlights.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$39.00
▲(29.83% Upside)
Technical Analysis
Ownership Overview
1.47% Insiders
35.69% Mutual Funds
1.14% Other Institutional Investors
35.46% Public Companies and
Individual Investors